Kura Oncology Development Candidate KO-539 Shows Robust Preclinical Anti-Tumor Activity in NPM1- and DNMT3A-Mutant AML

Stock Information for Kura Oncology Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Kura Oncology Inc.

Kura Oncology to Host Investor Day on November 16, 2017
Kura Oncology Reports Third Quarter 2017 Financial Results and Provides Corporate Update
Kura Oncology Announces Upcoming Presentations at American Society of Hematology Annual Meeting
Kura Oncology to Report Third Quarter 2017 Financial Results
Kura Oncology Lead Candidate Tipifarnib Shows Durable Anti-Tumor Activity in HRAS Mutant Head and Neck Cancer in AACR-NCI-EORTC Update
Kura Oncology Announces Late-Breaking Presentations for Tipifarnib in HRAS Mutant Squamous Head and Neck Cancer and for KO-539 in AML at Upcoming AACR-NCI-EORTC International Conference
Kura Oncology Announces Positive Phase 2 Study for Tipifarnib in HRAS Mutant Head and Neck Cancer
Kura Oncology to Participate in Citi's 12th Annual Biotech Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.